Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Allogeneic NK Cell Therapy in Patients With Refractory/Relapsed Lymphoma or Solid Tumor

NCT01212341 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT01212341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01212341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Allogeneic NK Cell Therapy in Patients With Refractory/Relapsed Lymphoma or Solid Tumor
Lead sponsor
Seoul National University Hospital
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2010
Completion date
March 31, 2013
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant lymphomas, solid tumors